New glaucoma drugs

There are several new glaucoma drugs that have been approved or are in development. Here are a few examples:

  1. Rhopressa (netarsudil): Approved by the FDA in 2017, Rhopressa is a once-daily eye drop that is used to treat open-angle glaucoma and ocular hypertension. It works by increasing the outflow of aqueous humor from the eye, which helps to lower intraocular pressure.
  2. Vyzulta (latanoprostene bunod): Approved by the FDA in 2017, Vyzulta is a once-daily eye drop that is used to treat open-angle glaucoma and ocular hypertension. It works by increasing the outflow of aqueous humor from the eye and reducing the production of aqueous humor.
  3. Xelpros (latanoprost): Approved by the FDA in 2017, Xelpros is a once-daily eye drop that is used to treat open-angle glaucoma and ocular hypertension. It works by increasing the outflow of aqueous humor from the eye and reducing the production of aqueous humor.
  4. Rocklatan (netarsudil and latanoprost): Approved by the FDA in 2020, Rocklatan is a once-daily eye drop that is used to treat open-angle glaucoma and ocular hypertension. It combines the active ingredients of Rhopressa and Xelpros, and works by increasing the outflow of aqueous humor from the eye and reducing the production of aqueous humor.
  5. Sirolimus: Sirolimus is an immunosuppressive drug that is being developed as a potential treatment for glaucoma. It works by inhibiting the activity of immune cells that can contribute to the development of glaucoma.
  6. AR-13324: AR-13324 is a small molecule that is being developed as a potential treatment for glaucoma. It works by increasing the outflow of aqueous humor from the eye and reducing the production of aqueous humor.
  7. Bimatoprost: Bimatoprost is a prostaglandin analog that is being developed as a potential treatment for glaucoma. It works by increasing the outflow of aqueous humor from the eye and reducing the production of aqueous humor.
  8. Brimonidine: Brimonidine is an alpha-2 adrenergic agonist that is being developed as a potential treatment for glaucoma. It works by reducing the production of aqueous humor and increasing the outflow of aqueous humor from the eye.
  9. Latanoprostene: Latanoprostene is a prostaglandin analog that is being developed as a potential treatment for glaucoma. It works by increasing the outflow of aqueous humor from the eye and reducing the production of aqueous humor.
  10. Netarsudil: Netarsudil is a rho-kinase inhibitor that is being developed as a potential treatment for glaucoma. It works by increasing the outflow of aqueous humor from the eye and reducing the production of aqueous humor.

It's important to note that these are just a few examples of new glaucoma drugs that are in development, and there may be other drugs that are being developed as well. Additionally, the effectiveness and safety of these drugs have not been fully established, and they may not be available for use in all countries.